PharmatrophiX

San Diego – November 04, 2026 -- Circular Genomics and PharmatrophiX have launched a biomarker collaboration that applies blood-based circular RNA (circRNA) profiling to LM11A-31, PharmatrophiX's first-in-class Alzheimer's candidate, with possible extension across the company's neurodegeneration pipeline.

Planned open-label study is the first test of the circRNA platform

The initial workstream centers on PharmatrophiX's planned open-label Alzheimer's biomarker study of LM11A-31, a small molecule targeting the p75 neurotrophin receptor (p75NTR). Circular Genomics will use its research-use-only CircPath platform to characterize baseline molecular heterogeneity and track pathway-level changes during treatment.